#1 Clinical Trials Search in Europe

3-((1S,2S)-1-(5-((S)-2,2-Dimethyltetrahydro-2H-Pyran-4-Yl)-2-((S)-3-(3-(4-Fluoro-1-Methyl-1H-Indazol-5-Yl)-2-Oxo-2,3-Dihydro-1H-Imidazol-1-Yl)-2-(4-Fluoro-3,5-Dimethylphenyl)-4-Methyl-4,5,6,7-Tetrahydro-2H-Pyrazolo[4,3-C]Pyridine-5-Carbonyl)-1H-Indol-1-Yl)-2-Methylcyclopropyl)-5-Oxo-1,2,4-Oxadiazol-4-Ide Hemicalcium

Orforglipron (LY3502970) is an investigational drug being studied in clinical trials for the treatment of type 2 diabetes and obesity. This oral medication is being evaluated for its potential to improve blood sugar control, promote weight loss, and reduce cardiovascular risks in adults with these conditions. Multiple phase 3 clinical trials are currently underway to assess the safety and efficacy of orforglipron compared to existing treatments like insulin and other diabetes medications.

Table of Contents

What is Orforglipron?

Orforglipron, also known by its scientific name 3-((1S,2S)-1-(5-((S)-2,2-DIMETHYLTETRAHYDRO-2H-PYRAN-4-YL)-2-((S)-3-(3-(4-FLUORO-1-METHYL-1H-INDAZOL-5-YL)-2-OXO-2,3-DIHYDRO-1H-IMIDAZOL-1-YL)-2-(4-FLUORO-3,5-DIMETHYLPHENYL)-4-METHYL-4,5,6,7-TETRAHYDRO-2H-PYRAZOLO[4,3-C]PYRIDINE-5-CARBONYL)-1H-INDOL-1-YL)-2-METHYLCYCLOPROPYL)-5-OXO-1,2,4-OXADIAZOL-4-IDE HEMICALCIUM or by its code name LY3502970, is a new medication being developed by Eli Lilly and Company for the treatment of Type 2 diabetes and obesity[1]. It is currently undergoing Phase 3 clinical trials to evaluate its safety and efficacy.

How Does Orforglipron Work?

While the exact mechanism of action is not fully described in the provided clinical trial information, orforglipron is likely a novel type of diabetes medication. It is taken orally once daily, which could offer a convenient alternative to injectable diabetes treatments[2].

What Conditions Does Orforglipron Treat?

Based on the clinical trials information, orforglipron is being studied for the treatment of:

  • Type 2 Diabetes: This is a chronic condition that affects how your body processes glucose (sugar)[3].
  • Obesity or Overweight: Excess body weight that can increase the risk of other health problems[3].
  • Cardiovascular Diseases: Conditions that affect the heart and blood vessels[1].
  • Chronic Kidney Disease: Long-term kidney damage that can worsen over time[1].

Current Clinical Trials

Orforglipron is currently being studied in several Phase 3 clinical trials:

  1. ACHIEVE-4 Study: Comparing orforglipron with insulin glargine in adults with Type 2 diabetes and obesity or overweight at increased cardiovascular risk[1].
  2. ATTAIN-2 Study: Investigating the efficacy and safety of orforglipron compared to placebo in adults with obesity or overweight and Type 2 diabetes[2].
  3. ATTAIN-1 Study: Evaluating orforglipron against placebo in adults with obesity or overweight with weight-related health issues[3].
  4. ACHIEVE-2 Study: Comparing orforglipron with dapagliflozin in adults with Type 2 diabetes and inadequate blood sugar control on metformin[4].
  5. ACHIEVE-5 Study: Testing orforglipron against placebo in adults with Type 2 diabetes and inadequate blood sugar control on insulin glargine, with or without metformin and/or SGLT-2 inhibitor[5].

Potential Benefits of Orforglipron

Based on the clinical trial objectives, orforglipron may offer several potential benefits:

  • Improved blood sugar control in people with Type 2 diabetes[4]
  • Weight loss in individuals with obesity or overweight[2]
  • Potential cardiovascular benefits for those at high risk[1]
  • Once-daily oral dosing, which may be more convenient than injectable treatments[5]

Possible Side Effects and Precautions

As orforglipron is still in clinical trials, its full side effect profile is not yet known. However, based on the exclusion criteria in the trials, people with the following conditions may need to exercise caution:

  • Type 1 diabetes[2]
  • History of pancreatitis (inflammation of the pancreas)[5]
  • History of hepatitis (inflammation of the liver)[5]
  • Congestive heart failure[5]
  • Medullary thyroid cancer or multiple endocrine neoplasia type 2[2]
  • Severe hypoglycemia or hypoglycemia unawareness[4]

Conclusion

Orforglipron (LY3502970) is a promising new medication being developed for the treatment of Type 2 diabetes and obesity. It is currently undergoing extensive clinical trials to evaluate its safety and efficacy. If successful, it could offer a new oral treatment option for people struggling with diabetes and weight management. However, as with any new medication, it’s important to wait for the results of these trials and subsequent regulatory approvals before drawing final conclusions about its effectiveness and safety profile.

Trial Name Main Objective Key Eligibility Criteria Primary Endpoint
ACHIEVE-4 To demonstrate non-inferiority to insulin glargine in MACE-4 events Type 2 diabetes, on 1-3 oral diabetes drugs, heart disease, HbA1c ≥7.0% Time to first occurrence of MACE-4
ATTAIN-2 To demonstrate superiority to placebo in body weight change Type 2 diabetes, obesity or overweight, on stable diabetes treatment Mean percent change in body weight at 72 weeks
ATTAIN-1 To demonstrate superiority to placebo in body weight change Obesity or overweight with weight-related comorbidities Mean percent change in body weight
ACHIEVE-2 To demonstrate non-inferiority to dapagliflozin in glycemic control Type 2 diabetes, on stable metformin treatment Change from baseline in HbA1c
ACHIEVE-5 To demonstrate superiority to placebo in glycemic control Type 2 diabetes, on insulin glargine with/without metformin and/or SGLT-2 inhibitor Change from baseline in HbA1c

FAQ

  • What is orforglipron? Orforglipron (LY3502970) is an investigational oral medication being studied for the treatment of type 2 diabetes and obesity. It is currently in phase 3 clinical trials to evaluate its safety and effectiveness.
  • What conditions is orforglipron being studied to treat? Orforglipron is being studied to treat type 2 diabetes, obesity, and overweight individuals with weight-related health issues. It is being evaluated for its potential to improve blood sugar control, promote weight loss, and reduce cardiovascular risks.
  • How is orforglipron administered? Orforglipron is administered orally as a capsule. It is being studied as a once-daily medication in the clinical trials.
  • What are the main objectives of the orforglipron clinical trials? The main objectives include evaluating orforglipron's effectiveness in controlling blood sugar levels, promoting weight loss, and assessing its safety profile. Some trials are comparing it to existing treatments like insulin or other diabetes medications.
  • Who is eligible to participate in these clinical trials? Eligibility varies by trial, but generally includes adults with type 2 diabetes, obesity, or overweight with related health issues. Some trials require participants to be on specific existing diabetes treatments. Detailed eligibility criteria are provided for each individual trial.

Ongoing Clinical Trials on 3-((1S,2S)-1-(5-((S)-2,2-Dimethyltetrahydro-2H-Pyran-4-Yl)-2-((S)-3-(3-(4-Fluoro-1-Methyl-1H-Indazol-5-Yl)-2-Oxo-2,3-Dihydro-1H-Imidazol-1-Yl)-2-(4-Fluoro-3,5-Dimethylphenyl)-4-Methyl-4,5,6,7-Tetrahydro-2H-Pyrazolo[4,3-C]Pyridine-5-Carbonyl)-1H-Indol-1-Yl)-2-Methylcyclopropyl)-5-Oxo-1,2,4-Oxadiazol-4-Ide Hemicalcium

  • Study on the Effectiveness of Orforglipron for Patients with Obstructive Sleep Apnea and Obesity or Overweight

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Czechia Germany

  • Study of Orforglipron for Adults with Type 2 Diabetes and Poor Blood Sugar Control on Insulin Glargine, with or without Metformin and/or SGLT-2 Inhibitor

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Romania

Glossary

  • Type 2 Diabetes: A chronic condition that affects the way your body metabolizes sugar (glucose), characterized by high blood sugar levels due to insulin resistance or insufficient insulin production.
  • Obesity: A complex disease involving an excessive amount of body fat, typically defined as a body mass index (BMI) of 30 or higher.
  • Cardiovascular Risk: The likelihood of developing heart disease or experiencing a cardiac event, such as a heart attack or stroke.
  • Hemoglobin A1c (HbA1c): A blood test that measures your average blood sugar levels over the past 2-3 months, used to diagnose and monitor diabetes.
  • Insulin Glargine: A long-acting type of insulin used to control blood sugar levels in people with diabetes.
  • Metformin: An oral medication commonly used as a first-line treatment for type 2 diabetes to help control blood sugar levels.
  • SGLT-2 Inhibitor: A class of diabetes medications that work by helping the kidneys remove excess sugar from the body through urine.
  • Glycemic Control: The management of blood sugar levels in people with diabetes, typically measured by HbA1c levels.
  • MACE-4: Major Adverse Cardiovascular Events, including heart attack, stroke, hospitalization for unstable angina, or cardiovascular death.
  • Pancreatitis: Inflammation of the pancreas, which can be acute or chronic and may cause severe abdominal pain.

References

  1. http://clinicaltrials.eu/trial/study-comparing-ly3502970-with-insulin-glargine-for-adults-with-type-2-diabetes-obesity-or-overweight-at-high-cardiovascular-risk/
  2. http://clinicaltrials.eu/trial/study-of-ly3502970-for-adults-with-obesity-or-overweight-and-type-2-diabetes/
  3. http://clinicaltrials.eu/trial/study-of-ly3502970-for-adults-with-obesity-or-overweight-and-related-health-issues/
  4. http://clinicaltrials.eu/trial/study-comparing-orforglipron-and-dapagliflozin-for-adults-with-type-2-diabetes-and-poor-blood-sugar-control-on-metformin/
  5. http://clinicaltrials.eu/trial/study-of-orforglipron-for-adults-with-type-2-diabetes-and-poor-blood-sugar-control-on-insulin-glargine-with-or-without-metformin-and-or-sglt-2-inhibitor/